AU2014318741B2 - Formulations for CGRP receptor antagonists - Google Patents

Formulations for CGRP receptor antagonists Download PDF

Info

Publication number
AU2014318741B2
AU2014318741B2 AU2014318741A AU2014318741A AU2014318741B2 AU 2014318741 B2 AU2014318741 B2 AU 2014318741B2 AU 2014318741 A AU2014318741 A AU 2014318741A AU 2014318741 A AU2014318741 A AU 2014318741A AU 2014318741 B2 AU2014318741 B2 AU 2014318741B2
Authority
AU
Australia
Prior art keywords
liquid pharmaceutical
pharmaceutical composition
composition according
polyethylene glycol
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014318741A
Other languages
English (en)
Other versions
AU2014318741A1 (en
Inventor
Leonardo R. Allain
Francis Flanagan
Lisa LUPTON
Majid Mahjour
Russell G. Maus
Rebecca NOFSINGER
Sutthilug Sotthivirat
Wei Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2014318741A1 publication Critical patent/AU2014318741A1/en
Application granted granted Critical
Publication of AU2014318741B2 publication Critical patent/AU2014318741B2/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014318741A 2013-09-16 2014-09-11 Formulations for CGRP receptor antagonists Active AU2014318741B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361878183P 2013-09-16 2013-09-16
US61/878,183 2013-09-16
PCT/US2014/055132 WO2015038736A2 (en) 2013-09-16 2014-09-11 Formulations for cgrp receptor antagonists

Publications (2)

Publication Number Publication Date
AU2014318741A1 AU2014318741A1 (en) 2016-03-10
AU2014318741B2 true AU2014318741B2 (en) 2018-12-06

Family

ID=52666511

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014318741A Active AU2014318741B2 (en) 2013-09-16 2014-09-11 Formulations for CGRP receptor antagonists

Country Status (13)

Country Link
US (3) US20160220552A1 (enExample)
EP (2) EP3915561A1 (enExample)
JP (1) JP6612234B2 (enExample)
KR (3) KR20220108207A (enExample)
CN (2) CN112545981A (enExample)
AU (1) AU2014318741B2 (enExample)
BR (1) BR112016005589B8 (enExample)
CA (1) CA2923426A1 (enExample)
IL (1) IL244356B (enExample)
MX (1) MX384611B (enExample)
RU (1) RU2690006C2 (enExample)
SA (1) SA516370737B1 (enExample)
WO (1) WO2015038736A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487706B (zh) * 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
KR20230107902A (ko) 2014-02-05 2023-07-18 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2021005497A1 (en) * 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
CN119350337A (zh) * 2024-12-24 2025-01-24 药康众拓(北京)医药科技有限公司 一类氘代哌啶酮酸酰胺氮杂茚满类cgrp抑制剂药物及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
US20120122899A1 (en) * 2010-11-12 2012-05-17 Merck Sharp & Dohme Corp. Piperidinone carboxamide azaindane cgrp receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739393B2 (en) * 1998-03-19 2001-10-11 Merck Sharp & Dohme Corp. Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations
GB9815801D0 (en) * 1998-07-21 1998-09-16 Merck & Co Inc Liquid polymeric compositions for controlled released bioactive substances
ITRM20020357A1 (it) * 2002-07-03 2004-01-05 Foscama Biomed Chim Farma Composizione liquida per la somministrazione orale di lorazepam.
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
US20120122899A1 (en) * 2010-11-12 2012-05-17 Merck Sharp & Dohme Corp. Piperidinone carboxamide azaindane cgrp receptor antagonists

Also Published As

Publication number Publication date
JP2016530316A (ja) 2016-09-29
EP3046923A4 (en) 2017-03-22
RU2016114537A3 (enExample) 2018-07-04
RU2690006C2 (ru) 2019-05-30
US20160220552A1 (en) 2016-08-04
AU2014318741A1 (en) 2016-03-10
KR102337994B1 (ko) 2021-12-13
BR112016005589B8 (pt) 2023-04-18
BR112016005589A8 (pt) 2018-02-06
IL244356B (en) 2020-09-30
CN105531275B (zh) 2020-12-18
IL244356A0 (en) 2016-04-21
WO2015038736A3 (en) 2015-11-12
US20210330660A1 (en) 2021-10-28
CN105531275A (zh) 2016-04-27
NZ717327A (en) 2021-10-29
RU2016114537A (ru) 2017-10-23
EP3046923A2 (en) 2016-07-27
EP3915561A1 (en) 2021-12-01
SA516370737B1 (ar) 2021-05-27
MX2016003394A (es) 2016-10-28
WO2015038736A2 (en) 2015-03-19
JP6612234B2 (ja) 2019-11-27
KR20220108207A (ko) 2022-08-02
CN112545981A (zh) 2021-03-26
BR112016005589B1 (pt) 2022-12-06
US20190070161A1 (en) 2019-03-07
KR20210153745A (ko) 2021-12-17
MX384611B (es) 2025-03-14
KR20160055149A (ko) 2016-05-17
CA2923426A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
AU2014318741B2 (en) Formulations for CGRP receptor antagonists
AU2016385362B2 (en) Long acting injectable formulations
US20100087392A1 (en) Complexes of ibuprofen, cyclodextrins and ternary agents and the use thereof in pharmaceutics
KR20110008055A (ko) 수성 약제학적 제제
EP4360623A1 (en) Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
NZ717327B2 (en) Formulations for cgrp receptor antagonists
HUE035543T2 (en) 6'-fluoro- (N-methyl or N, N-dimethyl) -4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3.4, B ] a pharmaceutical dosage form containing indole] -4-amine
US12396987B2 (en) Pharmaceutical composition with excellent storage stability
JP2008534610A (ja) イクサベピロンの投与方法
LU103368B1 (en) Pharmaceutical suspension of nilotinib
EP2874624B1 (en) Injectable antibiotic formulations and their methods of use
NL2028762B1 (en) Micelle-generating formulations for enhanced bioavailability
KR100896375B1 (ko) 주사용 의약 제제
EP2874623B1 (en) Injectable antibiotic formulations and their methods of use
AU2024216901A1 (en) Degarelix organic solvent formulations
NZ613138B2 (en) Injectable antibiotic formulations and their methods of use
NZ613138A (en) Injectable antibiotic formulations and their methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.